Btk Inhibitor Compounds Resolving Potency and Complexity Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for effective inhibitors of Bruton's tyrosine kinase (Btk) to address autoimmune disorders, inflammatory disorders, and cancers, as current solutions are inadequate in targeting these conditions effectively.
Innovation Solution
A series of compounds, including 5-(tert-butyl)-N-(2-methyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)picolinamide and others, are developed to inhibit Btk activity, which are designed to be used alone or in pharmaceutical compositions with excipients for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors are used to target Btk, then some therapeutic effect is achieved, but the inhibition potency is insufficient for effective treatment of autoimmune disorders, inflammatory disorders, and cancers
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Btk inhibitors to achieve higher potency. The compounds feature specific structural elements including a pyrrolo[2,3-d]pyrimidin-4-yl group combined with various substituted benzyl groups and carboxamide moieties. These structural parameter changes result in compounds with improved inhibition potency against Btk, addressing the insufficiency of current inhibitors while maintaining therapeutic effectiveness for autoimmune disorders, inflammatory disorders, and cancers
2Quantity of substance
If more potent Btk inhibitors are developed, then inhibition potency increases, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core pyrrolo[2,3-d]pyrimidin-4-yl group, substituted benzyl groups with various functional moieties (trifluoromethyl, chloro, cyano, carbamoyl, ethyl), and carboxamide linkers. This segmented approach allows for systematic optimization of each segment to achieve high potency while maintaining reasonable synthetic complexity through modular assembly of well-defined structural units
Solution Approach 2:
The patent applies universality through the use of a versatile core pyrrolo[2,3-d]pyrimidin-4-yl structure that can accommodate multiple different substituted benzyl groups and carboxamide variations. This universal core structure enables the development of a series of potent inhibitors with different substituent patterns, achieving high potency across multiple compounds while using a common synthetic framework that reduces overall design and synthesis complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate potent inhibition of Btk activity, offering potential therapeutic benefits for autoimmune disorders, inflammatory disorders, and cancers by effectively targeting Btk, as shown in studies measuring phosphorylated BTK inhibition in murine whole blood.
Implementation Method 1
These compounds demonstrate potent inhibition of Btk activity, offering potential therapeutic benefits for autoimmune disorders, inflammatory disorders, and cancers by effectively targeting Btk, as shown in studies measuring phosphorylated BTK inhibition in murine whole blood.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.